Cardiocore Lab Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Cardiocore Lab Inc. - overview
Location
Rockville, MD, US
Primary Industry
Biotechnology
About
Cardiocore Lab Inc. specializes in advanced cardiac monitoring solutions, providing critical diagnostic services that enhance patient care and clinical outcomes in cardiovascular health. Cardiocore Lab Inc. focuses on cardiac monitoring and diagnostics, operating from Rockville, US.
The company was acquired by CardioNet Inc. in August 2012. The current company valuation is USD 24. 177 mn, reflecting the strategic direction taken post-acquisition.
The latest funding round was a Series A, where the company raised USD 8. 000 mn, with notable investors including Aperture Venture Partners and Caxton Health Holdings. The company has completed a total of 3 deals to date. Cardiocore Lab Inc.
offers a comprehensive suite of connected monitoring and diagnostic solutions aimed at enhancing patient care for cardiovascular conditions. Their primary products include mobile cardiac telemetry (MCOT), extended Holter monitoring (ePatch), and various ECG solutions that support healthcare providers in diagnosing and managing patient populations effectively. These offerings cater to healthcare institutions, clinics, and outpatient facilities, particularly within the North American, European, and Asia-Pacific regions. Cardiocore Lab Inc.
generates revenue through direct sales of its medical devices and subscription-based services, supported by strategic B2B partnerships with healthcare providers. Their flagship products, MCOT and ePatch, play a crucial role in continuous cardiac monitoring. Revenue is derived from transactions involving purchase agreements and service contracts, ensuring compliance with regulatory standards while improving patient outcomes. Cardiocore Lab Inc.
aims to launch new products designed for enhanced cardiac monitoring in the upcoming year, focusing on innovations that address current clinical needs. The company plans to expand its market presence into Europe and Asia-Pacific by 2024, leveraging the recent Series A funding of USD 8. 000 mn to support product development and market entry initiatives. The acquisition by CardioNet Inc.
is expected to further facilitate these growth strategies, enhancing their operational capabilities.
Current Investors
Aperture Venture Partners, Maryland Department of Business and Economic Development, Caxton Health Holdings
Primary Industry
Biotechnology
Sub Industries
Bioinformatics
Website
www.cardiocore.com
Company Stage
Add-on
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.